Amplifon (AMFPF)
(Delayed Data from OTC)
$35.00 USD
0.00 (0.00%)
Updated May 17, 2024 09:38 AM ET
4-Sell of 5 4
C Value B Growth D Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AMFPF 35.00 0.00(0.00%)
Will AMFPF be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for AMFPF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AMFPF
Is GoodRx (GDRX) Outperforming Other Medical Stocks This Year?
Is Aadi Bioscience (AADI) Stock Outpacing Its Medical Peers This Year?
AMFPF: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Amplifon S.p.A. (AMFPF) Rating Upgrade to Buy
Is Aadi Bioscience (AADI) Outperforming Other Medical Stocks This Year?
New Strong Sell Stocks for January 16th
Other News for AMFPF
Amplifon price target raised by EUR 3 at Barclays
Amplifon S.p.A. (AMFPF) Q1 2024 Earnings Call Transcript
Amplifon price target raised by EUR 1 at Morgan Stanley
Amplifon price target lowered by EUR 1.60 at JPMorgan
Kepler Cheuvreux gets more bullish on Amplifon, upgrades shares